Page 171 - Haematologica Vol. 109 - July 2024

ARTICLE - MAIC in 3L+ FL
M.J. Maurer et al.
sequence of therapy for older patients with follicular lymphoma: SEER-Medicare analysis. Clin Lymphoma Myeloma Leuk. 2022;22(10):e938-e946.
14. Ayers EC, Margolis D, Landsburg DJ. Real world outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma receiving palliative intent therapies. Clin Lymphoma Myeloma Leuk. 2020;20(10):661-667.
15. Rutherford SC, Yin J, Pederson L, et al. Relevance of bone marrow biopsies for response assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. J Clin Oncol. 2023;41(2):336-342.
16. Thompson CA, Ghesquieres H, Maurer MJ, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014;32(31):3506-3512.
17. Goldman ML, Mao JJ, Strouse CS, et al. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer. 2021;127(18):3390-3402.
18. Neelapu SS, Locke FL, Bartlett NL, et al. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Adv. 2021;5(20):4149-4155.
19. Salles G, Schuster SJ, Dreyling M, et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(22):5835-5843.
20. Ghione P, Palomba ML, Patel A, et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/ refractory follicular lymphoma. Blood. 2022;140(8):851-860.
Haematologica | 109 July 2024
2185